Mei-Lin Tso

Degradation and poor permeability make the lungs a dead end for GLP-1 drugs.

Intranasal nanoparticles could deliver GLP-1 drugs to brain targets for neurological disease.

A needle-free nasal spray could reach patients' brains where pills and injections both fail.

Platform patents multiply value by stacking composition, method, and application claims together.

Enzymatic barriers and tight junctions make nasal delivery far harder than injection for peptides.

Nasal delivery could ease GLP-1 side effects while boosting brain concentrations.

Approved nanoparticles solve specific delivery failures free drugs cannot overcome.

Researchers race to unlock delivery methods as barrier blocks ninety-eight percent of brain drugs.

Intranasal delivery bypasses the blood-brain barrier via cranial nerves.

Many patients abandon GLP-1 drugs despite trial success rates.

Skin's molecular gatekeeping makes most peptide drugs impossible to deliver without injections.

Fear of needles keeps many chronic disease patients from taking life-saving injected medications.